The Clock Is Ticking, Will You Be Ready?
One Biotech Company is starting to see bigger volume by the day while also holding a strong support level around $2….the crazy part is that the leadership behind this team could be responsible for turning this small company into one with potential for a billion dollar pipeline!
Pluristem Therapeutics Inc. (PSTI) PLX-R18 Improves Hematopoietic Transplantation
Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading developer of placenta-based cell therapy products, announced today that Frontiers in Medicine has published key findings from a study of PLX-R18 that demonstrate the cells’ efficacy in improving human hematopoietic engraftment. The article titled, “Posttransplant Intramuscular Injection of PLX-R18 Mesenchymal-Like Adherent Stromal Cells Improves Human Hematopoietic Engraftment in A Murine Transplant Model” was published in the peer-reviewed journal’s February 2018 issue.